Literature DB >> 33644635

Anti-IgE: A treatment option in allergic rhinitis?

Oliver Pfaar1, Francesca Gehrt1, Hansen Li1,2, Stefan A Rudhart1,2, Alexander Nastev1,2, Boris A Stuck1,2, Stephan Hoch1,2.   

Abstract

BACKGROUND: Allergic rhinitis (AR) is the most common IgE-mediated allergic disease. Multiple clinical trials have demonstrated promising results on the AR treatment with biologics, in particular with the use of omalizumab - an anti-IgE antibody. Omalizumab has also been established in the routine management of allergic asthma and chronic idiopathic urticaria. However, currently there is no approved license for the use of biologics in AR in Germany.
MATERIALS AND METHODS: A systematic literature review has been completed including randomized controlled trials, meta-analyses, and reviews on the treatment of AR with omalizumab.
RESULTS: The systematic review demonstrates strong evidence supporting the use of omalizumab in the treatment of AR with regard to symptom control, safety profile, and management of comorbidities.
CONCLUSION: Omalizumab is a good and safe option in the treatment of AR in terms of symptom control and the management of pre-existing comorbidities. Further clinical trials with other biologics in the management of AR are needed and are expected to follow soon. © Dustri-Verlag Dr. K. Feistle.

Entities:  

Keywords:  allergen immunotherapy; allergic rhinitis; anti-IgE; biologics; omalizumab

Year:  2021        PMID： 33644635      PMCID： PMC7905705          DOI： 10.5414/ALX02205E

Source DB:  PubMed          Journal:  Allergol Select        ISSN： 2512-8957


  56 in total

1.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.

Authors:  E Adelroth; S Rak; T Haahtela; G Aasand; L Rosenhall; O Zetterstrom; A Byrne; K Champain; J Thirlwell; G D Cioppa; T Sandström
Journal:  J Allergy Clin Immunol       Date:  2000-08       Impact factor: 10.793

2.  Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.

Authors:  Joachim Kuehr; Jens Brauburger; Stefan Zielen; Uwe Schauer; Wolfgang Kamin; Andrea Von Berg; Wolfgang Leupold; Karl-Christian Bergmann; Claudia Rolinck-Werninghaus; Michael Gräve; Thomas Hultsch; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

3.  Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits.

Authors:  Jodi Crystal-Peters; Cheryl Neslusan; William H Crown; Amelito Torres
Journal:  J Allergy Clin Immunol       Date:  2002-01       Impact factor: 10.793

4.  Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.

Authors:  Aidan Long; Abdelkader Rahmaoui; Kenneth J Rothman; Eva Guinan; Mark Eisner; Mary S Bradley; Carlos Iribarren; Hubert Chen; Gillis Carrigan; Karin Rosén; Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2014-03-27       Impact factor: 10.793

Review 5.  Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis.

Authors:  T B Casale
Journal:  Am J Respir Crit Care Med       Date:  2001-10-15       Impact factor: 21.405

Review 6.  Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.

Authors:  Sophia Tsabouri; Xanthippi Tseretopoulou; Konstantinos Priftis; Evangelia E Ntzani
Journal:  J Allergy Clin Immunol Pract       Date:  2014 May-Jun

7.  Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.

Authors:  Satoshi Ogino; Toshikazu Nagakura; Kimihiro Okubo; Norio Sato; Masao Takahashi; Takeru Ishikawa
Journal:  Int Arch Allergy Immunol       Date:  2009-02-12       Impact factor: 2.749

8.  Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.

Authors:  T Nagakura; S Ogino; K Okubo; N Sato; M Takahashi; T Ishikawa
Journal:  Clin Exp Allergy       Date:  2007-12-07       Impact factor: 5.018

9.  The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.

Authors:  C Rolinck-Werninghaus; E Hamelmann; T Keil; M Kulig; K Koetz; B Gerstner; J Kuehr; S Zielen; U Schauer; W Kamin; A Von Berg; J Hammermann; B Weinkauf; G Weidinger; S Stenglein; U Wahn
Journal:  Allergy       Date:  2004-09       Impact factor: 13.146

10.  Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.

Authors:  A A Cruz; F Lima; E Sarinho; G Ayre; C Martin; H Fox; P J Cooper
Journal:  Clin Exp Allergy       Date:  2007-02       Impact factor: 5.018
View more
  1 in total

1.  Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD).

Authors:  Oliver Pfaar; Tobias Ankermann; Matthias Augustin; Petra Bubel; Sebastian Böing; Randolf Brehler; Peter A Eng; Peter J Fischer; Michael Gerstlauer; Eckard Hamelmann; Thilo Jakob; Jörg Kleine-Tebbe; Matthias Volkmar Kopp; Susanne Lau; Norbert Mülleneisen; Christoph Müller; Katja Nemat; Wolfgang Pfützner; Joachim Saloga; Klaus Strömer; Peter Schmid-Grendelmeier; Antje Schuster; Gunter Johannes Sturm; Christian Taube; Zsolt Szépfalusi; Christian Vogelberg; Martin Wagenmann; Wolfgang Wehrmann; Thomas Werfel; Stefan Wöhrl; Margitta Worm; Bettina Wedi; Susanne Kaul; Vera Mahler; Anja Schwalfenberg
Journal:  Allergol Select       Date:  2022-09-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.